This collaboration can be described as a "two-way push for professionalism and authority."
The joint efforts of Hongchen Group and two top-tier hospitals provide a solid guarantee for the scientific rigor and authority of the clinical trial.
The Department of Ophthalmology at the Children's Hospital Affiliated to Soochow University, a highly influential specialty ophthalmology department in Suzhou and the surrounding area, sees over 70,000 outpatients annually and has accumulated rich clinical experience in the diagnosis and treatment of pediatric refractive errors. This time, a dedicated research team of 13 senior physicians, led by Dr. Feng Kehong, Deputy Director (Administrative Director) and Chief Physician of the Department of Ophthalmology, will leverage their professional pediatric optometry capabilities to ensure the precise advancement of the adolescent trial.
The Department of Ophthalmology at Hebei Provincial People's Hospital, a key medical discipline in Hebei Province, boasts a large team of highly qualified professional physicians and is equipped with a full set of high-end optical coherence equipment. A dedicated research team of 15 professional physicians, led by Dr. Wang Jianmin, Deputy Director (Administrative Director) of the Department of Ophthalmology, Chief Physician, and Doctor of Medicine, will control the entire trial process with a rigorous scientific attitude.
This collaboration adheres to national standards. This clinical trial strictly follows the "Expert Consensus on Multi-Point Microlens Defocus Lenses for Myopia in China" standard, and adopts a multi-center randomized controlled trial design. The core focus is on two key indicators: axial length increase and equivalent spherical power change. At the same time, secondary endpoints such as visual comfort and wearing compliance are monitored. The plan is to comprehensively verify the actual effect of Hongchen defocus lenses in delaying the progression of myopia in adolescents aged 6-18 years through a systematic follow-up of 24 months.
Product = "Technological Compliance" + "Clinical Efficacy"
As a national high-tech enterprise and a Jiangsu Province advanced-level intelligent factory certified unit, Hongchen Group has always adhered to the core mission of "protecting eye health with technology" and deepened its development in the field of myopia prevention and control among teenagers. Relying on its core technological advantages such as intelligent production lines, user eye data resource databases, and professional nanoscale processing precision, the group promotes the integration of product development from "technological compliance" to "clinical efficacy," guided by medical concepts, and provides solid technical support for the combination of clinical research and industrial transformation.
Promoting Eye Health and Supporting Industry Development
Facing a myopia rate of 52.7% among children and adolescents in my country, the General Manager of Hongchen Group stated, "This clinical trial is not only a test of our defocus lens technology capabilities, but also a practical demonstration of our group's commitment to public health responsibility." In the future, Hongchen will be guided by clinical results, continuously optimizing its products, and leveraging its nationwide network of eye health retail stores to bring clinically validated myopia prevention and control solutions to various regional markets, contributing to the achievement of the "Healthy China" vision protection goals. We aim to drive the standardization and scientific development of China's optometry industry, using technology to safeguard children's clear vision!
We will attend the 2026 MIDO Optical Fair on Jan.31~Feb.2 ,welcome to our booth. You can know our products first, please check which items you are interested in and contact us freely. Now Summer is coming, Our photochromic lenses are hot sale , please find more details form our website. we also have RX preceitpion lens and so on.
Post time: Nov-21-2025